title: Cost-efficacy analysis of fluticasone propionate versus zafirlukast in patients with persistent asthma.
abstract: OBJECTIVE
  To compare the relative value of an inhaled corticosteroid, fluticasone propionate 88 microg twice daily, versus an oral leukotriene receptor antagonist, zafirlukast 20 mg twice daily, in patients with persistent asthma currently receiving short acting beta2-agonists alone.
  
  
  METHODS
  A cost-efficacy analysis using resource utilisation and clinical data obtained prospectively from a multicentre, randomised, double-blind, double-dummy, placebo-controlled 12-week clinical trial conducted in the US.
  
  
  CONCLUSIONS
  Third-party payor.
  
  
  METHODS
  A total of 451 corticosteroid-naive patients with persistent asthma were treated with either fluticasone propionate 88 microg twice daily or zafirlukast 20 mg twice daily. All patients were given salbutamol (albuterol) to be used as rescue medication. Data were examined using intent-to-treat analysis.
  
  
  RESULTS
  Mean daily per person cost-efficacy ratios using improvement in forced expiratory volume in 1 second (FEV1) [> or = 12% increase from baseline] were $US 3.47 for fluticasone propionate compared with $US 7.81 for zafirlukast (1999 values). The mean daily per person cost-efficacy ratios for symptom-free days obtained were $US 5.51 for fluticasone propionate compared with $US 14.98 for zafirlukast. These cost-efficacy ratios remained in favour of fluticasone propionate after a robust sensitivity analysis.
  
  
  CONCLUSIONS
  Treatment with fluticasone propionate 88 kg twice daily was the most cost effective treatment compared with zafirlukast 20 mg twice daily in this 12-week clinical trial. This analysis supports the use of fluticasone propionate 88 microg twice daily as first-line treatment in patients with persistent asthma previously treated with short-acting beta2-agonist alone.
authors.affiliation: Allergy and Asthma Center of El Paso, Texas 79925, USA. rmaacep@swbell.net
authors.forename: R
authors.initials: R
authors.lastname: Menendez
authors.forename: R H
authors.initials: RH
authors.lastname: Stanford
authors.forename: L
authors.initials: L
authors.lastname: Edwards
authors.forename: C
authors.initials: C
authors.lastname: Kalberg
authors.forename: K
authors.initials: K
authors.lastname: Rickard
mesh_terms: D000328:Adult; D000730:Androstadienes / Q000191:economics* / Q000627:therapeutic use; D018927:Anti-Asthmatic Agents / Q000191:economics* / Q000627:therapeutic use*; D001249:Asthma / Q000188:drug therapy* / Q000191:economics*; D003362:Cost-Benefit Analysis; D005260:Female; D000068298:Fluticasone; D006760:Hospitalization / Q000191:economics; D006801:Humans; D007211:Indoles; D008297:Male; D048448:Phenylcarbamates; D016032:Randomized Controlled Trials as Topic; D013449:Sulfonamides; D014105:Tosyl Compounds / Q000191:economics* / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D000730:Androstadienes; D018927:Anti-Asthmatic Agents; D007211:Indoles; D048448:Phenylcarbamates; D013449:Sulfonamides; D014105:Tosyl Compounds; D000068298:Fluticasone; C062735:zafirlukast